Yaron Werber
Stock Analyst at TD Cowen
(0.93)
# 2,775
Out of 4,413 analysts
25
Total ratings
31.58%
Success rate
-16.78%
Average return
Main Sectors:
Top Industries:
19 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EXEL Exelixis | Maintains: Buy | $25 → $27 | $21.17 | +27.54% | 1 | May 1, 2024 | |
| BGNE BeiGene | Maintains: Buy | $235 → $236 | $155.03 | +52.23% | 2 | Apr 24, 2024 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Buy | $59 → $61 | $42.84 | +42.39% | 1 | Apr 24, 2024 | |
| STOK Stoke Therapeutics | Upgrades: Buy | n/a | $11.19 | - | 1 | Mar 26, 2024 | |
| JSPR Jasper Therapeutics | Initiates: Outperform | n/a | $24.63 | - | 1 | Mar 18, 2024 | |
| IMRX Immuneering | Downgrades: Market Perform | n/a | $1.41 | - | 2 | Mar 15, 2024 | |
| TSVT 2seventy bio | Downgrades: Market Perform | n/a | $4.60 | - | 2 | Jan 31, 2024 | |
| CLDX Celldex Therapeutics | Initiates: Outperform | n/a | $38.64 | - | 1 | Dec 20, 2023 | |
| ARGX argenx SE | Maintains: Outperform | $612 → $641 | $383.70 | +67.06% | 3 | Dec 12, 2023 | |
| GBIO Generation Bio Co. | Downgrades: Market Perform | n/a | $2.91 | - | 1 | Oct 19, 2023 | |
| BNTX BioNTech SE | Maintains: Market Perform | $145 → $130 | $87.74 | +48.17% | 1 | Mar 28, 2023 | |
| FGEN FibroGen | Maintains: Market Perform | $15 → $25 | $1.17 | +2,036.75% | 1 | Feb 28, 2023 | |
| LEGN Legend Biotech | Initiates: Outperform | n/a | $43.06 | - | 1 | Nov 1, 2022 | |
| TIL Instil Bio | Downgrades: Market Perform | n/a | $10.57 | - | 2 | Nov 1, 2022 | |
| GMAB Genmab | Initiates: Market Perform | $38 | $28.17 | +34.90% | 1 | May 2, 2022 | |
| BLUE bluebird bio | Downgrades: Market Perform | n/a | $0.90 | - | 1 | Apr 6, 2022 | |
| ASND Ascendis Pharma | Initiates: Market Perform | $136 | $141.78 | -4.08% | 1 | Jan 6, 2022 | |
| IOBT IO Biotech | Initiates: Outperform | n/a | $1.54 | - | 1 | Nov 30, 2021 | |
| ROIV Roivant Sciences | Initiates: Outperform | n/a | $11.11 | - | 1 | Oct 26, 2021 |
Exelixis
May 1, 2024
Maintains: Buy
Price Target: $25 → $27
Current: $21.17
Upside: +27.54%
BeiGene
Apr 24, 2024
Maintains: Buy
Price Target: $235 → $236
Current: $155.03
Upside: +52.23%
Ultragenyx Pharmaceutical
Apr 24, 2024
Maintains: Buy
Price Target: $59 → $61
Current: $42.84
Upside: +42.39%
Stoke Therapeutics
Mar 26, 2024
Upgrades: Buy
Price Target: n/a
Current: $11.19
Upside: -
Jasper Therapeutics
Mar 18, 2024
Initiates: Outperform
Price Target: n/a
Current: $24.63
Upside: -
Immuneering
Mar 15, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $1.41
Upside: -
2seventy bio
Jan 31, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $4.60
Upside: -
Celldex Therapeutics
Dec 20, 2023
Initiates: Outperform
Price Target: n/a
Current: $38.64
Upside: -
argenx SE
Dec 12, 2023
Maintains: Outperform
Price Target: $612 → $641
Current: $383.70
Upside: +67.06%
Generation Bio Co.
Oct 19, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $2.91
Upside: -
BioNTech SE
Mar 28, 2023
Maintains: Market Perform
Price Target: $145 → $130
Current: $87.74
Upside: +48.17%
FibroGen
Feb 28, 2023
Maintains: Market Perform
Price Target: $15 → $25
Current: $1.17
Upside: +2,036.75%
Legend Biotech
Nov 1, 2022
Initiates: Outperform
Price Target: n/a
Current: $43.06
Upside: -
Instil Bio
Nov 1, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $10.57
Upside: -
Genmab
May 2, 2022
Initiates: Market Perform
Price Target: $38
Current: $28.17
Upside: +34.90%
bluebird bio
Apr 6, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $0.90
Upside: -
Ascendis Pharma
Jan 6, 2022
Initiates: Market Perform
Price Target: $136
Current: $141.78
Upside: -4.08%
IO Biotech
Nov 30, 2021
Initiates: Outperform
Price Target: n/a
Current: $1.54
Upside: -
Roivant Sciences
Oct 26, 2021
Initiates: Outperform
Price Target: n/a
Current: $11.11
Upside: -